References
Jacoby GA, Medeiros AA: More extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1991, 35: 1697–1704.
Bush K, Jacoby GA, Medeiros AA: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrobial Agents and Chemotherapy 1995, 39: 1211–1233.
Shannon KP, King A, Phillips I, Nicholas MH, Philippon A: Importation of organisms producing broad-spectrum SHV-group β-lactamases into the United Kingdom. Journal of Antimicrobial Chemotherapy 1990, 25: 343–351.
Katsanis GP, Spargo J, Ferraro MJ, Sutton L, Jacoby GA: Detection ofKlebsiella pneumoniae andEscherichia coli strains producing extended-spectrum β-lactamases. Journal of Clinical Microbiology 1994, 32: 691–696.
Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B: Evolution of plasmid-coded resistance to broad spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1985, 28: 302–307.
Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S: Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates ofKlebsiella pneumoniae andSerratia marcescens. Infection 1983, 11: 315–317.
Petit A, Sirot DL, Chanal CM, Sirot JL, Labia R, Gerbaud G, Cluzel RA: Novel plasmid-mediated β-lactamase in clinical isolates ofKlebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1988, 32: 626–630.
Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R: Transferable resistance to third-generation cephalosporins in clinical isolates ofKlebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. Journal of Antimicrobial Chemotherapy 1987, 20: 323–334.
Kitzis MD, Billot-Klein D, Goldstein FW, Williamson R, Nhieu GTV, Carlet J, Acar JF, Gutmann L: Dissemination of the novel plasmid-mediated β-lactamase CTX-1, which confers resistance to broad spectrum cephalosporins, and its inhibition by β-lactamase inhibitors. Antimicrobial Agents and Chemotherapy 1988, 32: 9–14.
Bauernfeind A, Hörl G: Novel R-factor borne β-lactamase ofEscherichia coli conferring resistance to cephalosporins. Infection 1987, 15: 257–259.
Spencer RC, Wheat PF, Winstanley TG, Cox DM, Plested SJ: Novel β-lactamase in a clinical isolate ofKlebsiella pneumoniae conferring unusual resistance to β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1987, 20: 919–921.
Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC Jr, Jacoby GA: Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrobial Agents and Chemotherapy 1990, 34: 2193–2199.
Meyers KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak ofKlebsiella infection resistant to late-generation cephalosporins. Annals of Internal Medicine 1993, 119: 353–358.
Sirot DL, Goldstein FW, Soussy CJ, Courtieu AL, Husson MO, Lemozy L, Morel MMC, Perez R, Quentin-Noury C, Reverdy ME, Scheftel JM, Rosenbaum M, Rezvani Y: Resistance to cefotaxime and seven other β-lactams in members of the familyEnterobacteriaceae: a 3 year survey in France. Antimicrobial Agents and Chemotherapy 1992, 36: 1677–1681.
Sirot D, Champs CD, Chanal C, Labia R, Darfeuille-Michaud A, Perrous R, Sirot J: Translocation of antibiotic resistance determinants including an extended-spectrum β-lactamase between conjugative plasmids ofKlebsiella pneumoniae andEscherichia coli. Antimicrobial Agents and Chemotherapy 1991, 35: 1576–1581.
Bradford P, Cherubin CE, Idemyor V, Rasmussen BA, Bush K: Multiply resistantKlebsiella pneumoniae from two Chicago hospitals: identification of the extended spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing β-lactamases in a single isolate. Antimicrobial Agents and Chemotherapy 1994, 38: 761–766.
Pangon B, Bizet C, Buré A, Pichon F, Philippon A, Regnier B, Gutmann L: In vivo selection of a cephamycin-resistant, porin-deficient mutant ofKlebsiella pneumoniae producing a TEM-3 β-lactamase. Journal of Infectious Diseases 1989, 159: 1005–1006.
Martinez-Martínez L, Hernández-Allés S, Alberti S, Tomás JM, Benedi V, Jacoby GA: In vivo selection of porin-deficient mutants ofKlebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1996, 40: 342–348.
Petit A, Gerbaud G, Sirot D, Courvalin P, Sirot J: Molecular epidemiology of TEM-3 (CTX-1) β-lactamase. Antimicrobial Agents and Chemotherapy 1990, 34: 219–224.
Rasmussen BA, Bradford PA, Quinn JP, Wiener J, Weinstein RA, Bush K: Genetically diverse ceftazidime resistant isolates from a single center: biochemical and genetic characterization of TEM-10 β-lactamases encoded by different nucleotide sequences. Antimicrobial Agents and Chemotherapy 1993, 37: 1989–1992.
Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palzkill T, Arvin AM: Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrobial Agents and Chemotherapy 1992, 36: 1991–1996.
Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, Projan SJ, Rahal JJ, Bush K: SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified inEscherichia coli isolates from hospitalized nursing home patients. Antimicrobial Agents and Chemotherapy 1995, 39: 899–905.
Quinn JR Miyashiro D, Sahm D, Flamm R, Bush K: Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates ofKlebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 1989, 33: 1451–1456.
Weber DA, Sanders CC, Bakken JS, Quinn JP: A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance inEscherichia coli. Journal of Infectious Diseases 1990, 162: 460–465.
Urban CM, Meyer KS, Mariano N, Rahal JJ, Flamm R, Rasmussen BA, Bush K: Identification of TEM-26 β-lactamase responsible for a major outbreak of ceftazidime resistantKlebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 1994, 38: 392–395.
Jarlier V, Nicolas M, Fournier G, Philippon A: Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents inEnterobacteriaceae: hospital prevalence and susceptibility patterns. Reviews of Infectious Diseases 1988, 10: 867–878.
Thomson KS, Sanders CC, Washington JA II: High-level resistance to cefotaxime and ceftazidime inKlebsiella pneumoniae isolates from Cleveland, Ohio. Antimicrobial Agents and Chemotherapy 1991, 35: 1001–1003.
Thomson KS, Sanders CC: Detection of extended-spectrum β-lactamases in members of the familyEnterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrobial Agents and Chemotherapy 1992, 36: 1877–1882.
Baquero F, Cantón R, Martinez-Beltrán J, Bolström A: The E-test as an epidemiological tool. Diagnostic Microbiology and Infectious Diseases 1992, 15: 483–487.
Sanchez ML, Barrtee MS, Jones RN: The E-test applied to susceptibility tests of gonococci, multiply-resistant enterococci andEnterobacteriaceae producing potent β-lactamases. Diagnostic Microbiology and Infectious Disease 1992, 15: 459–463.
Nüesch-Inderbinen MT, Hächler H, Kayser FH: Detection of extended-spectrum SHV β-lactamases in clinical isolates by a precise molecular genetic method and comparison with the E test ESBL. European Journal of Clinical Microbiology and Infectious Diseases 1996, 15: 398–402.
Podbielski A, Schönling J, Melzer B, Haase G: Different promoters of SHV-2 and SHV-2a β-lactamase lead to diverse levels of cefotaxime resistance in their bacterial producers. Journal of General Microbiology 1991, 137: 1667–1675.
Nüesch-Inderbinen MT, Hächler H, Kayser FH: New system based on site-directed mutagenesis for highly accurate comparison of resistance levels conferred by SHV β-lactamases. Antimicrobial Agents and Chemotherapy 1995, 39: 1726–1730.
Garbarg-Chenon A, Godard V, Labia R, Nicolas J-C: Nucleotide sequence of SHV-2 β-lactamase gene. Antimicrobial Agents and Chemotherapy 1990, 34: 1444–1446.
Sowek JA, Singer SB, Ohringer S, Malley MF, Dougherty TJ, Gougoutas JZ, Bush K: Substitution of lysine at position 104 or 240 of TEM-1pTZ18R β-lactamase enhances the effect of serine-164 substitution on the hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry 1991, 30: 3179–3188.
Rice LB, Yao JDC, Klimm K, Eliopoulos GM, Moellering RC Jr: Efficacy of different β-lactams against an extended-spectrum β-lactamase-producingKlebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrobial Agents and Chemotherapy 1991, 35: 1243–1244.
Jett BD, Ritchie DJ, Reichley R, Bailey TC, Sahm DF: Susceptibility of ESBL-producing organisms. Antimicrobial Agents and Chemotherapy 1995, 39: 1187–1190.
Knox JR: Extended-spectrum and inhibitor-resistant TEM-type β-lactamase: mutations, specificity and three-dimensional structure. Antimicrobial Agents and Chemotherapy 1995, 39: 2593–2601.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bush, K. Is it important to identify extended-spectrum beta-lactamase-producing isolates?. Eur. J. Clin. Microbiol. Infect. Dis. 15, 361–364 (1996). https://doi.org/10.1007/BF01690090
Issue Date:
DOI: https://doi.org/10.1007/BF01690090